DGAT1 and type 2 diabetes mellitus: PF-04620110 was the first pharmacological inhibitor of DGAT1 tested in healthy humans and patients with type 2 diabetes, and this drug demonstrated a dose-dependent reduction of postprandial TG excursions with varying degrees of gastrointestinal adverse effects (NCT01298518) [159].